Welcome to our dedicated page for Hemab Therapeutics Holdings SEC filings (Ticker: COAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Hemab Therapeutics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Hemab Therapeutics Holdings's regulatory disclosures and financial reporting.
Novo Holdings A/S, a Danish investment firm wholly owned by Novo Nordisk Foundation, reports a significant position in Hemab Therapeutics Holdings, Inc. common stock. Novo Holdings A/S beneficially owns 4,180,550 shares of Hemab’s common stock, representing 9.0% of the outstanding class.
Novo Holdings A/S has sole voting power and sole dispositive power over all 4,180,550 shares and no shared voting or dispositive power. The filing states that, based on the governance structure of Novo Holdings A/S and Novo Nordisk Foundation, the Foundation is not deemed to have beneficial ownership of these securities.
Hemab’s principal executive offices are located in Cambridge, Massachusetts, while Novo Holdings A/S’s principal business office is in Hellerup, Denmark. The certification section is marked not applicable, and the report is signed by Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S.
Hemab Therapeutics Holdings, Inc. is the subject of a Schedule 13G reporting that Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh collectively report beneficial ownership of 3,298,236 shares of common stock. This represents 7.06% of the common stock, calculated using 46,705,410 shares outstanding as of May 8, 2026, as reported by the company.
Dr. Aghazadeh, as portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures, is listed as a Reporting Person, with sole voting and dispositive power over these shares. The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P., and the Reporting Persons state that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Capital International Investors reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock on a Schedule 13G. The firm is deemed to beneficially own 3,603,876 shares, representing 7.7% of Hemab’s common stock, based on 46,705,410 shares believed to be outstanding. Capital International Investors has sole voting and sole dispositive power over all 3,603,876 shares and no shared voting or dispositive power.
Hemab Therapeutics Holdings, Inc. reported as a newly public, clinical-stage biotechnology company focused on blood coagulation disorders. In the quarter ended June 30, 2026, it recorded a net loss of $24.2 million, widening from $12.2 million a year earlier, driven primarily by increased research and development spending on sutacimig, HMB-002 and HMB-003.
For the first six months of 2026, the company’s net loss was $46.8 million. Operating expenses reached $49.7 million, including $39.8 million in research and development and $9.9 million in general and administrative costs, reflecting pipeline expansion and public-company infrastructure.
Hemab completed an IPO on May 4, 2026, issuing 19,262,500 shares at $18.00 per share, generating approximately $317.2 million in net proceeds, and converting 26,496,910 preferred shares into common stock. As of June 30, 2026, it held $457.5 million in cash, cash equivalents and marketable securities and had 46.7 million common shares outstanding. Management states this liquidity is expected to fund operations into 2029. The company discloses existing material weaknesses in internal control over financial reporting and is in the process of remediation.
Hemab Therapeutics Holdings, Inc. reported second quarter 2026 results, highlighting increased investment in its pipeline and a larger loss. For the quarter ended June 30, 2026, operating expenses were $26,079 thousand, up from $16,057 thousand a year earlier, leading to a net loss of $24,150 thousand versus $12,209 thousand in 2025.
The company strengthened its balance sheet in the first half of 2026, with cash and cash equivalents of $237,366 thousand and marketable securities of $220,094 thousand as of June 30, 2026, and total stockholders’ equity of $454,271 thousand. Net cash provided by financing activities was $317,119 thousand in the first six months.
Pipeline progress included FDA endorsement of the sutacimig data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with Phase 3 initiation planned in the second half of 2026. New HMB-002 data showed a ≥2.4-fold increase in Von Willebrand Factor and Factor VIII, and Hemab unveiled HMB-003, a novel peptide-based plasmin inhibitor initially targeting heavy menstrual bleeding.
Hemab Therapeutics Holdings, Inc. has been reported as held by a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of August 5, 2026, Invus Public Equities directly held 2,295,029 shares of common stock and Avicenna Life Sci Master Fund directly held 71,206 shares, for a combined position of 2,366,235 shares. Based on 46,705,410 shares outstanding as of May 8, 2026, the filing shows beneficial ownership percentages of 4.9% for several Invus-related entities and 5.1% for Raymond Debbane, who may be deemed to control multiple reporting entities. The group certifies that the securities are not held for the purpose of changing or influencing control of Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings Inc has a large institutional shareholder, FMR LLC, which reports beneficial ownership of 3,697,837 shares of the company’s common stock (CUSIP 423494103). This position represents 7.9% of the outstanding common stock as of the reported date.
FMR LLC reports sole voting and sole dispositive power over 3,697,837 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 3,697,837 shares but no voting power. One or more other persons may have rights to dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.
Hemab Therapeutics Holdings, Inc. has a significant shareholder group led by Sofinnova. Sofinnova Crossover II SLP, together with Sofinnova Partners SAS and the members of Sofinnova’s investment committee, report beneficial ownership of 2,511,212 shares of common stock of Hemab.
This holding represents 5.4% of the common stock, with ownership stated as of June 30, 2026. The percentage is based on 46,705,410 shares outstanding as of May 8, 2026, as disclosed by Hemab. The Sofinnova entities may be deemed to have sole voting and dispositive power over these shares, while the investment committee members may be deemed to share such powers, though they expressly disclaim being beneficial owners for certain legal purposes.
Hemab Therapeutics Holdings, Inc. reported that investment entities affiliated with RA Capital Management, a ten percent owner, made open-market purchases of Common Stock. On June 16, 2026, an affiliated fund bought 61,523 shares at a weighted average price of $24.98 per share, with trades ranging from $24.55 to $25.00. On June 15, 2026, another affiliated fund bought 6,146 shares at a weighted average price of $24.89 per share, within a $24.65 to $25.00 range. Following these transactions, one indirect position reported 6,444,637 shares, while related fund holdings were reported at 354,938 and 1,009,052 shares, all held indirectly and subject to pecuniary-interest-only ownership disclaimers.
Hemab Therapeutics Holdings, Inc. disclosed that investment vehicles associated with RA Capital made open-market purchases of its Common Stock. On May 19, an RA Capital-related entity bought 3,802 shares at a weighted average price of $24.97 per share, and on May 20 another purchase of 996 shares was made at a weighted average price of $24.94 per share. Following these transactions, RA Capital-affiliated entities indirectly held 6,376,968 shares of Hemab Therapeutics Common Stock. The filing notes that shares are held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus funds, and that the Adviser, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.